Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 16,542 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Connective Tissue Disease Clear all

Conditions: Melanoma
Interventions: Poly ICLC, leukapheresis; Drug · Procedure
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Cancer, Breast, Cancer-related Problem/Condition, Quality of Life, Hormone Dependent Neoplasms, Adherence, Medication
Interventions: "My Guide" (psychoeducation & self-management program); Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Plaque-type Psoriasis
Interventions: CJM112, Secukinumab, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 18
States / cities: Anniston, Alabama • Anaheim, California • Encino, California + 14 more

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Povorcitinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • Farmington, Connecticut + 19 more

Conditions: Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma, Susceptible FGFR3 Genetic Alterations, FGFR3, FGFR3 Overexpression, FGFR3 Receptor, FGFR3 Protein Overexpression, Ovarian Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Lung Cancer, Gastric Cancer
Interventions: [225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab; Drug · Biological
Lead sponsor: Fusion Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Duarte, California • San Francisco, California • Iowa City, Iowa + 1 more

Conditions: Melanoma
Interventions: administration of ipilimumab10mg/kg, administration of ipilimumab 3mg/kg + HDI; Drug
Lead sponsor: Diwakar Davar; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV
Interventions: IFx-Hu2.0; Biological
Lead sponsor: TuHURA Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Skin Laxity, Lipodystrophy
Interventions: Rotational fractional resection (1.5mm diameter device); Device
Lead sponsor: Recros Medica, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Campbell, California • Newport Beach, California • Roseville, California + 3 more

Conditions: Lichen Planus, Oral Leukoplakia, Mouth Neoplasms
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 110 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2025
U.S. locations: 6
States / cities: San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 3 more

Conditions: Atopy, Atopic Dermatitis Eczema, Wheezing, Food Allergy in Infants
Interventions: Not listed
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 0 Days to 7 Days
Enrollment: 221 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Atopic Dermatitis
Interventions: Oral EP262, Placebo; Drug
Lead sponsor: Escient Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Birmingham, Alabama • Miami Lakes, Florida • Plainfield, Indiana + 6 more

Conditions: Melanoma, Metastatic Melanoma
Interventions: SAbR, Ipilimumab, Nivolumab; Radiation · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Advanced Solid Tumor, Metastatic Breast Cancer
Interventions: Abraxane, ORIN1001; Drug
Lead sponsor: Orinove, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 20
States / cities: Gilbert, Arizona • Tucson, Arizona • Burbank, California + 16 more

Conditions: Malignant Breast Neoplasm
Interventions: Ultrasonography, Automated Breast Ultrasound; Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infections, Lipodystrophy, Metabolic Diseases, Nutrition Disorders
Interventions: NucleomaxX, Tenofovir Disoproxil Fumarate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Metastatic Breast Cancer, Leptomeningeal Disease
Interventions: Tucatinib, Trastuzumab, Capecitabine; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 9
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 6 more

Conditions: Gingival Recession
Interventions: Allograft Material ADM-S, Allograft Material ADM-D; Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 89 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Gastrointestinal Stromal Tumor
Interventions: imatinib mesylate, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Advanced Melanoma
Interventions: Vigil™ Vaccine; Biological
Lead sponsor: Gradalis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Dermatitis, Atopic, Pruritus
Interventions: 3% kanuka oil; Other
Lead sponsor: Nexgen Dermatologics, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Boynton Beach, Florida

Conditions: Kaposi Sarcoma
Interventions: CYT107; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Women's Health: Neoplasm of Breast, Menopause, Premature, Body Image, Sexual Dysfunction, Cancer, Breast
Interventions: EMBRACE (Empowerment through Mind and Body Reclamation After Cancer Experience); Behavioral
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Sarcoma, Metastatic Disease, Bony Sites
Interventions: SBRT; Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 4 Years to 40 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 5
States / cities: Stanford, California • Washington D.C., District of Columbia • Baltimore, Maryland + 2 more

Conditions: Metastatic Melanoma
Interventions: Pembrolizumab; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells

A Research Study for Latina Women With Breast Cancer

Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma

pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma

CONFORM: Rotational Fractional Resection for Submental Contouring

Biomarkers for Oral Cancer

Breast Milk: Influence of the Micro-transcriptome Profile on Atopy in Children Over Time

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis

SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients

ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer

A Study to Compare the Effectiveness of Two Types of Ultrasound Technologies in Women Who Have Had Breast Cancer

Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Gingival Augmentation and Root Coverage With Superficial and Deep Cut Acellular Dermal Matrices

Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery

Phase II FANG™ in Advanced Melanoma

The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis

Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)

Nurse-led Mind-body Intervention on Sexual Health for Breast Cancer Survivors

Stereotactic Radiation Therapy for Pediatric Sarcomas

Imaging FDG Flare in Melanoma